MS: high-altitude yak gene protects and repairs myelin in early study

A genetic twist that lets yaks thrive where oxygen is scarce could point scientists toward a new way to protect and rebuild the insulating layer around nerve fibers — a discovery that may reshape thinking about treatments for multiple sclerosis. Researchers who traced this adaptation from animals on the Tibetan Plateau into laboratory mice found evidence that the same molecular pathway helps preserve and restore myelin, the crucial sheath that enables neurons to transmit signals efficiently.

The study, led by a team at Shanghai Jiao Tong University School of Medicine and published in Neuron, moves beyond immune suppression and into the biology of repair: a gene variant called Retsat appears to boost production of a vitamin A–derived metabolite, ATDR, which in turn accelerates the formation and maturation of myelin-producing cells in mice.

Why a high-altitude gene became the focus of neurological research

Scientists have long been curious about how animals native to extreme environments maintain normal brain function despite chronic low oxygen. On the Tibetan Plateau — averaging roughly 14,700 feet above sea level — yaks and other species carry unique genetic changes that help them cope with hypoxia. One such change affects the Retsat gene, and earlier genomic surveys flagged it as a candidate for further study.

Rather than limiting the inquiry to evolutionary biology, the research team asked a translational question: could the same adaptation that protects animals in thin air also shield or repair nervous tissue in mammals facing myelin damage? To answer that, they recreated the gene’s effects in mice and put the animals through tests designed to reveal how their brains and behavior responded to oxygen stress and injury.

Evidence from mice: preserved function and faster myelin repair

In controlled experiments, newborn mice engineered to carry the Retsat variation were exposed to low-oxygen conditions comparable to living above 13,000 feet for about a week. Compared with mice that had the standard version of the gene, the Retsat group performed better on tasks assessing memory, learning, and social responses.

Brain tissue analyses showed that these mice maintained a thicker, healthier myelin layer around nerve fibers. When researchers created localized myelin damage to mimic demyelinating conditions, the Retsat-bearing mice regenerated myelin more rapidly and more completely than controls. The damaged sites also showed an increase in mature oligodendrocytes — the cells responsible for building the myelin sheath.

Key experimental observations

• Behavioral advantages: Improved cognitive and social test results after hypoxic exposure.
• Structural protection: Higher levels of myelin surrounding axons in Retsat mice.
• Enhanced repair: Faster remyelination and more mature oligodendrocytes at injury sites.

ATDR emerges as the likely molecular mediator

Digging into the biochemical changes, the team discovered that mice with the adaptive Retsat variant had increased production of ATDR, a metabolite formed from vitamin A. The mutation appears to upregulate enzymatic activity that converts vitamin A into downstream compounds capable of influencing cell maturation.

Laboratory tests showed that treatment with ATDR reduced the severity of an MS-like condition induced in mice and improved motor abilities. These results support a model in which the Retsat mutation confers its protective and regenerative effects at least in part by tipping vitamin A metabolism toward substances that promote oligodendrocyte development and myelin synthesis.

What this means for multiple sclerosis and other myelin disorders

At present, most MS therapies aim to dampen the immune system to prevent further attacks on myelin. The new findings open a different avenue: enhancing the body’s innate capacity to rebuild the myelin sheath. Because both Retsat and ATDR are part of natural biological pathways, they may offer therapeutic angles that complement existing treatments.

Potential clinical implications include:

• Developing small molecules or biologics that mimic ATDR’s effects on oligodendrocytes.
• Using metabolic modulation to support remyelination after autoimmune attacks or ischemic injury.
• Exploring vitamin A–based strategies for neonatal brain injuries that impair myelination and for age-related vascular contributions to cognitive decline.

Steps the researchers took and the road ahead

Lead author Professor Liang Zhang and colleagues emphasize that these experiments are an early demonstration of principle. The study combined genetic engineering, controlled hypoxia, behavioral testing, and biochemical analysis to trace a path from an evolutionary adaptation to a potential therapeutic target.

Next steps will include testing safety and efficacy in larger animal models, determining optimal dosing strategies for ATDR-like compounds, and mapping any off-target effects of altering vitamin A metabolism. The team notes that translating a discovery rooted in evolutionary biology into human treatments will require careful clinical development and regulatory evaluation.

You might also like:

• DMT, the spirit molecule, protects brain from stroke in mice, study finds
• 10-minute intensive workout triggers powerful anti-cancer effects, study finds
• How Chernobyl mutated stray dogs
• Vitamin K may form basis for new treatment for neurodegenerative diseases
• Desert mouse defies aging: study could reshape human longevity research

Michael Thompson

Michael Thompson is an experienced journalist covering U.S. and global news. With ten years on the front lines, he breaks down political and economic stories that matter. His precise writing and keen attention to detail help you grasp the real‑world impact of every event.